India (Commonwealth Union)_ The pharmaceutical giant Cipla has introduced a point-of-care testing equipment for numerous non-communicable illnesses and other medical disorders, expanding its footprint in the diagnostics market. Cipla’s Cippoint device, a new addition to its product line for diagnostic laboratories, offers a vast array of testing parameters, including heart indicators, diabetes, infectious illnesses, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers.
According to the business, the device is authorized by the European In-Vitro Diagnostic Device Directive, assuring accurate testing solutions. Cippoint, a quantitative immunofluorescence analyzer, enables healthcare providers to obtain test findings in 3 to 15 minutes, therefore expediting the clinical decision-making process. Cipla stated that Cippoint’s automated technology and user-friendly interface make it suitable for usage in rural regions, mobile vans, and isolated locations with little infrastructure, as the product intends to enable smaller healthcare facilities to perform accurate point-of-care testing.
In its annual report, Cipla stated that its three-year plan from 2020 to 2023 intends to provide solutions for the whole care continuum, from simple and early diagnosis through effective treatment and monitoring. In FY 2021-22, the business also introduced a variety of covid-19-related diagnostic tests such as antibodies and fast antigen. According to the company’s annual report, “Cipla’s focus continues on realizing commercial opportunities beyond respiratory and complex generics and injectables, particularly in the space of co-developing biosimilars, inhalation devices, diagnostics solutions, new-age technology platforms and digitized business models”.
Achin Gupta, CEO, India Business at Cipla, stated, “We are actively working towards delivering innovative solutions that enable prompt and effective diagnosis, thereby plugging gaps in the diagnostic ecosystem”. According to a report by Praxis Global Alliance, a global management consulting and advisory firm, the Indian medical diagnostic market is projected to reach $20 billion by 2026, up from $10 billion in 2021, a 14 percent increase, with the diagnostic segment attracting more investments and pharmaceutical companies entering the market.
